MEDICATION SAFETY ISSUES
Sound-alike/look-alike issues:
VoSol® may be confused with Vexol®
U.S. BRAND NAMES — Acetasol® HC; VoSol® HC
PHARMACOLOGIC CATEGORY
Otic Agent, Anti-infective
DOSING: ADULTS — Otitis externa (superficial): Otic: Instill 3-5 drops in ear(s) every 4-6 hours
DOSING: PEDIATRIC — Children ≥ 3 years: Refer to adult dosing.
DOSING: ELDERLY — Refer to adult dosing.
DOSAGE FORMS — Excipient information presented when available (limited, particularly for generics); consult specific product labeling.
Solution, otic [drops]:
Acetasol® HC: Acetic acid 2%, propylene glycol diacetate 3%, and hydrocortisone 1% (10 mL) [contains benzethonium chloride]
VoSol® HC: Acetic acid 2%, propylene glycol diacetate 3%, and hydrocortisone 1% (10 mL) [contains benzethonium chloride]
DOSAGE FORMS: CONCISE
Solution, otic [drops]:
Acetasol® HC, VoSol® HC: Acetic acid 2%, propylene glycol diacetate 3%, and hydrocortisone 1% (10 mL)
GENERIC EQUIVALENT AVAILABLE — Yes
ADMINISTRATION — After removing cerumen and debris, solution may be applied by inserting a cotton wick into the ear canal and saturating with the solution. Wick may remain in place for 24 hours and then removed; however, drops should continue to be instilled into ear canal as long as indicated.
USE — Treatment of superficial infections of the external auditory canal caused by organisms susceptible to the action of the antimicrobial, complicated by swelling
ADVERSE REACTIONS SIGNIFICANT — Frequency not defined: Otic: Transient burning or stinging may be noticed occasionally when the solution is first instilled into the acutely inflamed ear
CONTRAINDICATIONS — Hypersensitivity to acetic acid, propylene glycol, hydrocortisone, or any component of the formulation; perforated tympanic membrane; herpes simplex; vaccinia, and varicella
METABOLISM / TRANSPORT EFFECTS — Hydrocortisone: Substrate of CYP3A4 (minor); Induces CYP3A4 (weak)
DRUG INTERACTIONS
Acetylcholinesterase Inhibitors: Corticosteroids (Systemic) may enhance the adverse/toxic effect of Acetylcholinesterase Inhibitors. Increased muscular weakness may occur. Risk C: Monitor therapy
Aminoglutethimide: May increase the metabolism of Corticosteroids (Systemic). Risk C: Monitor therapy
Amphotericin B: Corticosteroids (Systemic) may enhance the hypokalemic effect of Amphotericin B. Risk C: Monitor therapy
Antacids: May decrease the bioavailability of Corticosteroids (Oral). Risk D: Consider therapy modification
Antidiabetic Agents: Corticosteroids (Systemic) may diminish the hypoglycemic effect of Antidiabetic Agents. In some instances, corticosteroid-mediated HPA axis suppression has led to episodes of acute adrenal crisis, which may manifest as enhanced hypoglycemia, particularly in the setting of insulin or other antidiabetic agent use. Risk C: Monitor therapy
Antifungal Agents (Azole Derivatives, Systemic): May decrease the metabolism of Corticosteroids (Systemic). Risk C: Monitor therapy
Aprepitant: May increase the serum concentration of Corticosteroids (Systemic). Risk D: Consider therapy modification
Barbiturates: May increase the metabolism of Corticosteroids (Systemic). Risk C: Monitor therapy
Bile Acid Sequestrants: May decrease the absorption of Corticosteroids (Oral). Risk C: Monitor therapy
Calcitriol: Corticosteroids (Systemic) may diminish the therapeutic effect of Calcitriol. Risk C: Monitor therapy
Calcium Channel Blockers (Nondihydropyridine): May decrease the metabolism of Corticosteroids (Systemic). Risk C: Monitor therapy
Corticorelin: Corticosteroids may diminish the therapeutic effect of Corticorelin. Specifically, the plasma ACTH response to corticorelin may be blunted by recent or current corticosteroid therapy. Risk C: Monitor therapy
CycloSPORINE: Corticosteroids (Systemic) may increase the serum concentration of CycloSPORINE. CycloSPORINE may increase the serum concentration of Corticosteroids (Systemic). Risk C: Monitor therapy
Echinacea: May diminish the therapeutic effect of Immunosuppressants. Risk D: Consider therapy modification
Estrogen Derivatives: May increase the serum concentration of Corticosteroids (Systemic). Risk C: Monitor therapy
Fluconazole: May decrease the metabolism of Corticosteroids (Systemic). Risk C: Monitor therapy
Fosaprepitant: May increase the serum concentration of Corticosteroids (Systemic). The active metabolite aprepitant is likely responsible for this effect. Risk D: Consider therapy modification
Isoniazid: Corticosteroids (Systemic) may decrease the serum concentration of Isoniazid. Risk C: Monitor therapy
Leflunomide: Immunosuppressants may enhance the adverse/toxic effect of Leflunomide. Specifically, the risk for hematologic toxicity such as pancytopenia, agranulocytosis, and/or thrombocytopenia may be increased. Management: Consider not using a leflunomide loading dose in patients receiving other immunosuppressants. Patients receiving both leflunomide and another immunosuppressant should be monitored for bone marrow suppression at least monthly. Risk D: Consider therapy modification
Loop Diuretics: Corticosteroids (Systemic) may enhance the hypokalemic effect of Loop Diuretics. Risk C: Monitor therapy
Macrolide Antibiotics: May decrease the metabolism of Corticosteroids (Systemic). Exceptions: Azithromycin; Dirithromycin [Off Market]; Spiramycin. Risk D: Consider therapy modification
Mitotane: May decrease the serum concentration of Corticosteroids (Systemic). Risk D: Consider therapy modification
Natalizumab: Immunosuppressants may enhance the adverse/toxic effect of Natalizumab. Specifically, the risk of concurrent infection may be increased. Risk X: Avoid combination
Neuromuscular-Blocking Agents (Nondepolarizing): May enhance the adverse neuromuscular effect of Corticosteroids (Systemic). Increased muscle weakness, possibly progressing to polyneuropathies and myopathies, may occur. Risk D: Consider therapy modification
NSAID (COX-2 Inhibitor): Corticosteroids (Systemic) may enhance the adverse/toxic effect of NSAID (COX-2 Inhibitor). Risk C: Monitor therapy
NSAID (Nonselective): Corticosteroids (Systemic) may enhance the adverse/toxic effect of NSAID (Nonselective). Risk C: Monitor therapy
P-Glycoprotein Inducers: May decrease the serum concentration of P-Glycoprotein Substrates. P-glycoprotein inducers may also further limit the distribution of p-glycoprotein substrates to specific cells/tissues/organs where p-glycoprotein is present in large amounts (e.g., brain, T-lymphocytes, testes, etc.). Risk C: Monitor therapy
P-Glycoprotein Inhibitors: May increase the serum concentration of P-Glycoprotein Substrates. P-glycoprotein inhibitors may also enhance the distribution of p-glycoprotein substrates to specific cells/tissues/organs where p-glycoprotein is present in large amounts (e.g., brain, T-lymphocytes, testes, etc.). Risk C: Monitor therapy
Primidone: May increase the metabolism of Corticosteroids (Systemic). Risk C: Monitor therapy
Quinolone Antibiotics: May enhance the adverse/toxic effect of Corticosteroids (Systemic). Risk of tendon-related side effects, including tendonitis and rupture, may be enhanced. Risk C: Monitor therapy
Rifamycin Derivatives: May increase the metabolism of Corticosteroids (Systemic). Risk C: Monitor therapy
Salicylates: May enhance the adverse/toxic effect of Corticosteroids (Systemic). These specifically include gastrointestinal ulceration and bleeding. Corticosteroids (Systemic) may decrease the serum concentration of Salicylates. Withdrawal of corticosteroids may result in salicylate toxicity. Risk C: Monitor therapy
Thiazide Diuretics: Corticosteroids (Systemic) may enhance the hypokalemic effect of Thiazide Diuretics. Risk C: Monitor therapy
Trastuzumab: May enhance the neutropenic effect of Immunosuppressants. Risk C: Monitor therapy
Vaccines (Inactivated): Immunosuppressants may diminish the therapeutic effect of Vaccines (Inactivated). Risk C: Monitor therapy
Vaccines (Live): Immunosuppressants may enhance the adverse/toxic effect of Vaccines (Live). Vaccinial infections may develop. Immunosuppressants may diminish the therapeutic effect of Vaccines (Live). Risk X: Avoid combination
Warfarin: Corticosteroids (Systemic) may enhance the anticoagulant effect of Warfarin. Risk C: Monitor therapy
PRICING — (data from drugstore.com)
Solution (Acetasol HC)
2-1% (10): $209.97
PATIENT INFORMATION — See individual agent for Hydrocortisone.
Showing posts with label Acetic acid. Show all posts
Showing posts with label Acetic acid. Show all posts
Acetic acid, propylene glycol diacetate, and hydrocortisone
MEDICATION SAFETY ISSUES
Sound-alike/look-alike issues:
VoSol® may be confused with Vexol®
U.S. BRAND NAMES — Acetasol® HC; VoSol® HC
PHARMACOLOGIC CATEGORY
Otic Agent, Anti-infective
DOSING: ADULTS — Otitis externa (superficial): Otic: Instill 3-5 drops in ear(s) every 4-6 hours
DOSING: PEDIATRIC — Children ≥ 3 years: Refer to adult dosing.
DOSING: ELDERLY — Refer to adult dosing.
DOSAGE FORMS — Excipient information presented when available (limited, particularly for generics); consult specific product labeling.
Solution, otic [drops]:
Acetasol® HC: Acetic acid 2%, propylene glycol diacetate 3%, and hydrocortisone 1% (10 mL) [contains benzethonium chloride]
VoSol® HC: Acetic acid 2%, propylene glycol diacetate 3%, and hydrocortisone 1% (10 mL) [contains benzethonium chloride]
DOSAGE FORMS: CONCISE
Solution, otic [drops]:
Acetasol® HC, VoSol® HC: Acetic acid 2%, propylene glycol diacetate 3%, and hydrocortisone 1% (10 mL)
GENERIC EQUIVALENT AVAILABLE — Yes
ADMINISTRATION — After removing cerumen and debris, solution may be applied by inserting a cotton wick into the ear canal and saturating with the solution. Wick may remain in place for 24 hours and then removed; however, drops should continue to be instilled into ear canal as long as indicated.
USE — Treatment of superficial infections of the external auditory canal caused by organisms susceptible to the action of the antimicrobial, complicated by swelling
ADVERSE REACTIONS SIGNIFICANT — Frequency not defined: Otic: Transient burning or stinging may be noticed occasionally when the solution is first instilled into the acutely inflamed ear
CONTRAINDICATIONS — Hypersensitivity to acetic acid, propylene glycol, hydrocortisone, or any component of the formulation; perforated tympanic membrane; herpes simplex; vaccinia, and varicella
METABOLISM / TRANSPORT EFFECTS — Hydrocortisone: Substrate of CYP3A4 (minor); Induces CYP3A4 (weak)
DRUG INTERACTIONS
Acetylcholinesterase Inhibitors: Corticosteroids (Systemic) may enhance the adverse/toxic effect of Acetylcholinesterase Inhibitors. Increased muscular weakness may occur. Risk C: Monitor therapy
Aminoglutethimide: May increase the metabolism of Corticosteroids (Systemic). Risk C: Monitor therapy
Amphotericin B: Corticosteroids (Systemic) may enhance the hypokalemic effect of Amphotericin B. Risk C: Monitor therapy
Antacids: May decrease the bioavailability of Corticosteroids (Oral). Risk D: Consider therapy modification
Antidiabetic Agents: Corticosteroids (Systemic) may diminish the hypoglycemic effect of Antidiabetic Agents. In some instances, corticosteroid-mediated HPA axis suppression has led to episodes of acute adrenal crisis, which may manifest as enhanced hypoglycemia, particularly in the setting of insulin or other antidiabetic agent use. Risk C: Monitor therapy
Antifungal Agents (Azole Derivatives, Systemic): May decrease the metabolism of Corticosteroids (Systemic). Risk C: Monitor therapy
Aprepitant: May increase the serum concentration of Corticosteroids (Systemic). Risk D: Consider therapy modification
Barbiturates: May increase the metabolism of Corticosteroids (Systemic). Risk C: Monitor therapy
Bile Acid Sequestrants: May decrease the absorption of Corticosteroids (Oral). Risk C: Monitor therapy
Calcitriol: Corticosteroids (Systemic) may diminish the therapeutic effect of Calcitriol. Risk C: Monitor therapy
Calcium Channel Blockers (Nondihydropyridine): May decrease the metabolism of Corticosteroids (Systemic). Risk C: Monitor therapy
Corticorelin: Corticosteroids may diminish the therapeutic effect of Corticorelin. Specifically, the plasma ACTH response to corticorelin may be blunted by recent or current corticosteroid therapy. Risk C: Monitor therapy
CycloSPORINE: Corticosteroids (Systemic) may increase the serum concentration of CycloSPORINE. CycloSPORINE may increase the serum concentration of Corticosteroids (Systemic). Risk C: Monitor therapy
Echinacea: May diminish the therapeutic effect of Immunosuppressants. Risk D: Consider therapy modification
Estrogen Derivatives: May increase the serum concentration of Corticosteroids (Systemic). Risk C: Monitor therapy
Fluconazole: May decrease the metabolism of Corticosteroids (Systemic). Risk C: Monitor therapy
Fosaprepitant: May increase the serum concentration of Corticosteroids (Systemic). The active metabolite aprepitant is likely responsible for this effect. Risk D: Consider therapy modification
Isoniazid: Corticosteroids (Systemic) may decrease the serum concentration of Isoniazid. Risk C: Monitor therapy
Leflunomide: Immunosuppressants may enhance the adverse/toxic effect of Leflunomide. Specifically, the risk for hematologic toxicity such as pancytopenia, agranulocytosis, and/or thrombocytopenia may be increased. Management: Consider not using a leflunomide loading dose in patients receiving other immunosuppressants. Patients receiving both leflunomide and another immunosuppressant should be monitored for bone marrow suppression at least monthly. Risk D: Consider therapy modification
Loop Diuretics: Corticosteroids (Systemic) may enhance the hypokalemic effect of Loop Diuretics. Risk C: Monitor therapy
Macrolide Antibiotics: May decrease the metabolism of Corticosteroids (Systemic). Exceptions: Azithromycin; Dirithromycin [Off Market]; Spiramycin. Risk D: Consider therapy modification
Mitotane: May decrease the serum concentration of Corticosteroids (Systemic). Risk D: Consider therapy modification
Natalizumab: Immunosuppressants may enhance the adverse/toxic effect of Natalizumab. Specifically, the risk of concurrent infection may be increased. Risk X: Avoid combination
Neuromuscular-Blocking Agents (Nondepolarizing): May enhance the adverse neuromuscular effect of Corticosteroids (Systemic). Increased muscle weakness, possibly progressing to polyneuropathies and myopathies, may occur. Risk D: Consider therapy modification
NSAID (COX-2 Inhibitor): Corticosteroids (Systemic) may enhance the adverse/toxic effect of NSAID (COX-2 Inhibitor). Risk C: Monitor therapy
NSAID (Nonselective): Corticosteroids (Systemic) may enhance the adverse/toxic effect of NSAID (Nonselective). Risk C: Monitor therapy
P-Glycoprotein Inducers: May decrease the serum concentration of P-Glycoprotein Substrates. P-glycoprotein inducers may also further limit the distribution of p-glycoprotein substrates to specific cells/tissues/organs where p-glycoprotein is present in large amounts (e.g., brain, T-lymphocytes, testes, etc.). Risk C: Monitor therapy
P-Glycoprotein Inhibitors: May increase the serum concentration of P-Glycoprotein Substrates. P-glycoprotein inhibitors may also enhance the distribution of p-glycoprotein substrates to specific cells/tissues/organs where p-glycoprotein is present in large amounts (e.g., brain, T-lymphocytes, testes, etc.). Risk C: Monitor therapy
Primidone: May increase the metabolism of Corticosteroids (Systemic). Risk C: Monitor therapy
Quinolone Antibiotics: May enhance the adverse/toxic effect of Corticosteroids (Systemic). Risk of tendon-related side effects, including tendonitis and rupture, may be enhanced. Risk C: Monitor therapy
Rifamycin Derivatives: May increase the metabolism of Corticosteroids (Systemic). Risk C: Monitor therapy
Salicylates: May enhance the adverse/toxic effect of Corticosteroids (Systemic). These specifically include gastrointestinal ulceration and bleeding. Corticosteroids (Systemic) may decrease the serum concentration of Salicylates. Withdrawal of corticosteroids may result in salicylate toxicity. Risk C: Monitor therapy
Thiazide Diuretics: Corticosteroids (Systemic) may enhance the hypokalemic effect of Thiazide Diuretics. Risk C: Monitor therapy
Trastuzumab: May enhance the neutropenic effect of Immunosuppressants. Risk C: Monitor therapy
Vaccines (Inactivated): Immunosuppressants may diminish the therapeutic effect of Vaccines (Inactivated). Risk C: Monitor therapy
Vaccines (Live): Immunosuppressants may enhance the adverse/toxic effect of Vaccines (Live). Vaccinial infections may develop. Immunosuppressants may diminish the therapeutic effect of Vaccines (Live). Risk X: Avoid combination
Warfarin: Corticosteroids (Systemic) may enhance the anticoagulant effect of Warfarin. Risk C: Monitor therapy
PRICING — (data from drugstore.com)
Solution (Acetasol HC)
2-1% (10): $209.97
PATIENT INFORMATION — See individual agent for Hydrocortisone.
Sound-alike/look-alike issues:
VoSol® may be confused with Vexol®
U.S. BRAND NAMES — Acetasol® HC; VoSol® HC
PHARMACOLOGIC CATEGORY
Otic Agent, Anti-infective
DOSING: ADULTS — Otitis externa (superficial): Otic: Instill 3-5 drops in ear(s) every 4-6 hours
DOSING: PEDIATRIC — Children ≥ 3 years: Refer to adult dosing.
DOSING: ELDERLY — Refer to adult dosing.
DOSAGE FORMS — Excipient information presented when available (limited, particularly for generics); consult specific product labeling.
Solution, otic [drops]:
Acetasol® HC: Acetic acid 2%, propylene glycol diacetate 3%, and hydrocortisone 1% (10 mL) [contains benzethonium chloride]
VoSol® HC: Acetic acid 2%, propylene glycol diacetate 3%, and hydrocortisone 1% (10 mL) [contains benzethonium chloride]
DOSAGE FORMS: CONCISE
Solution, otic [drops]:
Acetasol® HC, VoSol® HC: Acetic acid 2%, propylene glycol diacetate 3%, and hydrocortisone 1% (10 mL)
GENERIC EQUIVALENT AVAILABLE — Yes
ADMINISTRATION — After removing cerumen and debris, solution may be applied by inserting a cotton wick into the ear canal and saturating with the solution. Wick may remain in place for 24 hours and then removed; however, drops should continue to be instilled into ear canal as long as indicated.
USE — Treatment of superficial infections of the external auditory canal caused by organisms susceptible to the action of the antimicrobial, complicated by swelling
ADVERSE REACTIONS SIGNIFICANT — Frequency not defined: Otic: Transient burning or stinging may be noticed occasionally when the solution is first instilled into the acutely inflamed ear
CONTRAINDICATIONS — Hypersensitivity to acetic acid, propylene glycol, hydrocortisone, or any component of the formulation; perforated tympanic membrane; herpes simplex; vaccinia, and varicella
METABOLISM / TRANSPORT EFFECTS — Hydrocortisone: Substrate of CYP3A4 (minor); Induces CYP3A4 (weak)
DRUG INTERACTIONS
Acetylcholinesterase Inhibitors: Corticosteroids (Systemic) may enhance the adverse/toxic effect of Acetylcholinesterase Inhibitors. Increased muscular weakness may occur. Risk C: Monitor therapy
Aminoglutethimide: May increase the metabolism of Corticosteroids (Systemic). Risk C: Monitor therapy
Amphotericin B: Corticosteroids (Systemic) may enhance the hypokalemic effect of Amphotericin B. Risk C: Monitor therapy
Antacids: May decrease the bioavailability of Corticosteroids (Oral). Risk D: Consider therapy modification
Antidiabetic Agents: Corticosteroids (Systemic) may diminish the hypoglycemic effect of Antidiabetic Agents. In some instances, corticosteroid-mediated HPA axis suppression has led to episodes of acute adrenal crisis, which may manifest as enhanced hypoglycemia, particularly in the setting of insulin or other antidiabetic agent use. Risk C: Monitor therapy
Antifungal Agents (Azole Derivatives, Systemic): May decrease the metabolism of Corticosteroids (Systemic). Risk C: Monitor therapy
Aprepitant: May increase the serum concentration of Corticosteroids (Systemic). Risk D: Consider therapy modification
Barbiturates: May increase the metabolism of Corticosteroids (Systemic). Risk C: Monitor therapy
Bile Acid Sequestrants: May decrease the absorption of Corticosteroids (Oral). Risk C: Monitor therapy
Calcitriol: Corticosteroids (Systemic) may diminish the therapeutic effect of Calcitriol. Risk C: Monitor therapy
Calcium Channel Blockers (Nondihydropyridine): May decrease the metabolism of Corticosteroids (Systemic). Risk C: Monitor therapy
Corticorelin: Corticosteroids may diminish the therapeutic effect of Corticorelin. Specifically, the plasma ACTH response to corticorelin may be blunted by recent or current corticosteroid therapy. Risk C: Monitor therapy
CycloSPORINE: Corticosteroids (Systemic) may increase the serum concentration of CycloSPORINE. CycloSPORINE may increase the serum concentration of Corticosteroids (Systemic). Risk C: Monitor therapy
Echinacea: May diminish the therapeutic effect of Immunosuppressants. Risk D: Consider therapy modification
Estrogen Derivatives: May increase the serum concentration of Corticosteroids (Systemic). Risk C: Monitor therapy
Fluconazole: May decrease the metabolism of Corticosteroids (Systemic). Risk C: Monitor therapy
Fosaprepitant: May increase the serum concentration of Corticosteroids (Systemic). The active metabolite aprepitant is likely responsible for this effect. Risk D: Consider therapy modification
Isoniazid: Corticosteroids (Systemic) may decrease the serum concentration of Isoniazid. Risk C: Monitor therapy
Leflunomide: Immunosuppressants may enhance the adverse/toxic effect of Leflunomide. Specifically, the risk for hematologic toxicity such as pancytopenia, agranulocytosis, and/or thrombocytopenia may be increased. Management: Consider not using a leflunomide loading dose in patients receiving other immunosuppressants. Patients receiving both leflunomide and another immunosuppressant should be monitored for bone marrow suppression at least monthly. Risk D: Consider therapy modification
Loop Diuretics: Corticosteroids (Systemic) may enhance the hypokalemic effect of Loop Diuretics. Risk C: Monitor therapy
Macrolide Antibiotics: May decrease the metabolism of Corticosteroids (Systemic). Exceptions: Azithromycin; Dirithromycin [Off Market]; Spiramycin. Risk D: Consider therapy modification
Mitotane: May decrease the serum concentration of Corticosteroids (Systemic). Risk D: Consider therapy modification
Natalizumab: Immunosuppressants may enhance the adverse/toxic effect of Natalizumab. Specifically, the risk of concurrent infection may be increased. Risk X: Avoid combination
Neuromuscular-Blocking Agents (Nondepolarizing): May enhance the adverse neuromuscular effect of Corticosteroids (Systemic). Increased muscle weakness, possibly progressing to polyneuropathies and myopathies, may occur. Risk D: Consider therapy modification
NSAID (COX-2 Inhibitor): Corticosteroids (Systemic) may enhance the adverse/toxic effect of NSAID (COX-2 Inhibitor). Risk C: Monitor therapy
NSAID (Nonselective): Corticosteroids (Systemic) may enhance the adverse/toxic effect of NSAID (Nonselective). Risk C: Monitor therapy
P-Glycoprotein Inducers: May decrease the serum concentration of P-Glycoprotein Substrates. P-glycoprotein inducers may also further limit the distribution of p-glycoprotein substrates to specific cells/tissues/organs where p-glycoprotein is present in large amounts (e.g., brain, T-lymphocytes, testes, etc.). Risk C: Monitor therapy
P-Glycoprotein Inhibitors: May increase the serum concentration of P-Glycoprotein Substrates. P-glycoprotein inhibitors may also enhance the distribution of p-glycoprotein substrates to specific cells/tissues/organs where p-glycoprotein is present in large amounts (e.g., brain, T-lymphocytes, testes, etc.). Risk C: Monitor therapy
Primidone: May increase the metabolism of Corticosteroids (Systemic). Risk C: Monitor therapy
Quinolone Antibiotics: May enhance the adverse/toxic effect of Corticosteroids (Systemic). Risk of tendon-related side effects, including tendonitis and rupture, may be enhanced. Risk C: Monitor therapy
Rifamycin Derivatives: May increase the metabolism of Corticosteroids (Systemic). Risk C: Monitor therapy
Salicylates: May enhance the adverse/toxic effect of Corticosteroids (Systemic). These specifically include gastrointestinal ulceration and bleeding. Corticosteroids (Systemic) may decrease the serum concentration of Salicylates. Withdrawal of corticosteroids may result in salicylate toxicity. Risk C: Monitor therapy
Thiazide Diuretics: Corticosteroids (Systemic) may enhance the hypokalemic effect of Thiazide Diuretics. Risk C: Monitor therapy
Trastuzumab: May enhance the neutropenic effect of Immunosuppressants. Risk C: Monitor therapy
Vaccines (Inactivated): Immunosuppressants may diminish the therapeutic effect of Vaccines (Inactivated). Risk C: Monitor therapy
Vaccines (Live): Immunosuppressants may enhance the adverse/toxic effect of Vaccines (Live). Vaccinial infections may develop. Immunosuppressants may diminish the therapeutic effect of Vaccines (Live). Risk X: Avoid combination
Warfarin: Corticosteroids (Systemic) may enhance the anticoagulant effect of Warfarin. Risk C: Monitor therapy
PRICING — (data from drugstore.com)
Solution (Acetasol HC)
2-1% (10): $209.97
PATIENT INFORMATION — See individual agent for Hydrocortisone.
Acetic acid
MEDICATION SAFETY ISSUES
Sound-alike/look-alike issues:
Acetic acid for irrigation may be confused with glacial acetic acid
VoSol® may be confused with Vexol®
PHARMACOLOGIC CATEGORY
Otic Agent, Anti-infective
Topical Skin Product
DOSING: ADULTS
Irrigation (Note: Dosage of an irrigating solution depends on the capacity or surface area of the structure being irrigated):
For continuous irrigation of the urinary bladder with 0.25% acetic acid irrigation, the rate of administration will approximate the rate of urine flow; usually 500-1500 mL/24 hours
For periodic irrigation of an indwelling urinary catheter to maintain patency, about 50 mL of 0.25% acetic acid irrigation is required
Otitis externa: Otic: Insert saturated wick; keep moist 24 hours; remove wick and instill 5 drops 3-4 times/day
DOSING: ELDERLY — Refer to adult dosing.
DOSAGE FORMS — Excipient information presented when available (limited, particularly for generics); consult specific product labeling.
Solution for irrigation: 0.25% (250 mL, 500 mL, 1000 mL)
Solution, otic: 2% (15 mL)
DOSAGE FORMS: CONCISE
Solution for irrigation: 0.25% (250 mL, 500 mL, 1000 mL)
Solution, otic: 2% (15 mL)
GENERIC EQUIVALENT AVAILABLE — Yes
ADMINISTRATION — Not for internal intake or I.V. infusion; topical use or irrigation use only.
USE — Irrigation of the bladder; treatment of superficial bacterial infections of the external auditory canal
ADVERSE REACTIONS SIGNIFICANT — <1% (Limited to important or life-threatening): Hematuria, systemic acidosis, urologic pain
CONTRAINDICATIONS — Hypersensitivity to acetic acid or any component of the formulation; during transurethral procedures
WARNINGS / PRECAUTIONS
Concerns related to adverse effects: Acidosis: Systemic acidosis may result from absorption. Bladder irritation: Use of irrigation in patients with mucosal lesions of urinary bladder may cause irritation.
Other warnings/precautions: Administration: Not for internal intake or I.V. infusion; topical use or irrigation use only.
DRUG INTERACTIONS — There are no known significant interactions.
PREGNANCY RISK FACTOR — C (show table)
INTERNATIONAL BRAND NAMES — Aquaear (AU); Earcalm (GB, IE); Suym Otico (PE)
Sound-alike/look-alike issues:
Acetic acid for irrigation may be confused with glacial acetic acid
VoSol® may be confused with Vexol®
PHARMACOLOGIC CATEGORY
Otic Agent, Anti-infective
Topical Skin Product
DOSING: ADULTS
Irrigation (Note: Dosage of an irrigating solution depends on the capacity or surface area of the structure being irrigated):
For continuous irrigation of the urinary bladder with 0.25% acetic acid irrigation, the rate of administration will approximate the rate of urine flow; usually 500-1500 mL/24 hours
For periodic irrigation of an indwelling urinary catheter to maintain patency, about 50 mL of 0.25% acetic acid irrigation is required
Otitis externa: Otic: Insert saturated wick; keep moist 24 hours; remove wick and instill 5 drops 3-4 times/day
DOSING: ELDERLY — Refer to adult dosing.
DOSAGE FORMS — Excipient information presented when available (limited, particularly for generics); consult specific product labeling.
Solution for irrigation: 0.25% (250 mL, 500 mL, 1000 mL)
Solution, otic: 2% (15 mL)
DOSAGE FORMS: CONCISE
Solution for irrigation: 0.25% (250 mL, 500 mL, 1000 mL)
Solution, otic: 2% (15 mL)
GENERIC EQUIVALENT AVAILABLE — Yes
ADMINISTRATION — Not for internal intake or I.V. infusion; topical use or irrigation use only.
USE — Irrigation of the bladder; treatment of superficial bacterial infections of the external auditory canal
ADVERSE REACTIONS SIGNIFICANT — <1% (Limited to important or life-threatening): Hematuria, systemic acidosis, urologic pain
CONTRAINDICATIONS — Hypersensitivity to acetic acid or any component of the formulation; during transurethral procedures
WARNINGS / PRECAUTIONS
Concerns related to adverse effects: Acidosis: Systemic acidosis may result from absorption. Bladder irritation: Use of irrigation in patients with mucosal lesions of urinary bladder may cause irritation.
Other warnings/precautions: Administration: Not for internal intake or I.V. infusion; topical use or irrigation use only.
DRUG INTERACTIONS — There are no known significant interactions.
PREGNANCY RISK FACTOR — C (show table)
INTERNATIONAL BRAND NAMES — Aquaear (AU); Earcalm (GB, IE); Suym Otico (PE)
Acetic acid
MEDICATION SAFETY ISSUES
Sound-alike/look-alike issues:
Acetic acid for irrigation may be confused with glacial acetic acid
VoSol® may be confused with Vexol®
PHARMACOLOGIC CATEGORY
Otic Agent, Anti-infective
Topical Skin Product
DOSING: ADULTS
Irrigation (Note: Dosage of an irrigating solution depends on the capacity or surface area of the structure being irrigated):
For continuous irrigation of the urinary bladder with 0.25% acetic acid irrigation, the rate of administration will approximate the rate of urine flow; usually 500-1500 mL/24 hours
For periodic irrigation of an indwelling urinary catheter to maintain patency, about 50 mL of 0.25% acetic acid irrigation is required
Otitis externa: Otic: Insert saturated wick; keep moist 24 hours; remove wick and instill 5 drops 3-4 times/day
DOSING: ELDERLY — Refer to adult dosing.
DOSAGE FORMS — Excipient information presented when available (limited, particularly for generics); consult specific product labeling.
Solution for irrigation: 0.25% (250 mL, 500 mL, 1000 mL)
Solution, otic: 2% (15 mL)
DOSAGE FORMS: CONCISE
Solution for irrigation: 0.25% (250 mL, 500 mL, 1000 mL)
Solution, otic: 2% (15 mL)
GENERIC EQUIVALENT AVAILABLE — Yes
ADMINISTRATION — Not for internal intake or I.V. infusion; topical use or irrigation use only.
USE — Irrigation of the bladder; treatment of superficial bacterial infections of the external auditory canal
ADVERSE REACTIONS SIGNIFICANT — <1% (Limited to important or life-threatening): Hematuria, systemic acidosis, urologic pain
CONTRAINDICATIONS — Hypersensitivity to acetic acid or any component of the formulation; during transurethral procedures
WARNINGS / PRECAUTIONS
Concerns related to adverse effects: Acidosis: Systemic acidosis may result from absorption. Bladder irritation: Use of irrigation in patients with mucosal lesions of urinary bladder may cause irritation.
Other warnings/precautions: Administration: Not for internal intake or I.V. infusion; topical use or irrigation use only.
DRUG INTERACTIONS — There are no known significant interactions.
PREGNANCY RISK FACTOR — C (show table)
INTERNATIONAL BRAND NAMES — Aquaear (AU); Earcalm (GB, IE); Suym Otico (PE)
Sound-alike/look-alike issues:
Acetic acid for irrigation may be confused with glacial acetic acid
VoSol® may be confused with Vexol®
PHARMACOLOGIC CATEGORY
Otic Agent, Anti-infective
Topical Skin Product
DOSING: ADULTS
Irrigation (Note: Dosage of an irrigating solution depends on the capacity or surface area of the structure being irrigated):
For continuous irrigation of the urinary bladder with 0.25% acetic acid irrigation, the rate of administration will approximate the rate of urine flow; usually 500-1500 mL/24 hours
For periodic irrigation of an indwelling urinary catheter to maintain patency, about 50 mL of 0.25% acetic acid irrigation is required
Otitis externa: Otic: Insert saturated wick; keep moist 24 hours; remove wick and instill 5 drops 3-4 times/day
DOSING: ELDERLY — Refer to adult dosing.
DOSAGE FORMS — Excipient information presented when available (limited, particularly for generics); consult specific product labeling.
Solution for irrigation: 0.25% (250 mL, 500 mL, 1000 mL)
Solution, otic: 2% (15 mL)
DOSAGE FORMS: CONCISE
Solution for irrigation: 0.25% (250 mL, 500 mL, 1000 mL)
Solution, otic: 2% (15 mL)
GENERIC EQUIVALENT AVAILABLE — Yes
ADMINISTRATION — Not for internal intake or I.V. infusion; topical use or irrigation use only.
USE — Irrigation of the bladder; treatment of superficial bacterial infections of the external auditory canal
ADVERSE REACTIONS SIGNIFICANT — <1% (Limited to important or life-threatening): Hematuria, systemic acidosis, urologic pain
CONTRAINDICATIONS — Hypersensitivity to acetic acid or any component of the formulation; during transurethral procedures
WARNINGS / PRECAUTIONS
Concerns related to adverse effects: Acidosis: Systemic acidosis may result from absorption. Bladder irritation: Use of irrigation in patients with mucosal lesions of urinary bladder may cause irritation.
Other warnings/precautions: Administration: Not for internal intake or I.V. infusion; topical use or irrigation use only.
DRUG INTERACTIONS — There are no known significant interactions.
PREGNANCY RISK FACTOR — C (show table)
INTERNATIONAL BRAND NAMES — Aquaear (AU); Earcalm (GB, IE); Suym Otico (PE)
Acetic acid, propylene glycol diacetate, and hydrocortisone
U.S. BRAND NAMES — Acetasol® HC; VoSol® HC
PHARMACOLOGIC CATEGORY Otic Agent, Anti-infective
DOSING: ADULTS — Otitis externa (superficial): Otic: Instill 3-5 drops in ear(s) every 4-6 hours
DOSING: PEDIATRIC — Children 3 years: Refer to adult dosing.
DOSING: ELDERLY — Refer to adult dosing.
DOSAGE FORMS — Excipient information presented when available (limited, particularly for generics); consult specific product labeling.
Solution, otic drops: Acetic acid 2%, propylene glycol diacetate 3%, and hydrocortisone 1% (10 mL)
DOSAGE FORMS: CONCISE Solution, otic drops: Acetic acid 2%, propylene glycol diacetate 3%, and hydrocortisone 1% (10 mL) Acetasol® HC, VoSol® HC: Acetic acid 2%, propylene glycol diacetate 3%, and hydrocortisone 1% (10 mL)
GENERIC EQUIVALENT AVAILABLE — Yes
ADMINISTRATION — After removing cerumen and debris, solution may be applied by inserting a cotton wick into the ear canal and saturating with the solution. Wick may remain in place for 24 hours and then removed; however, drops should continue to be instilled into ear canal as long as indicated.
USE — Treatment of superficial infections of the external auditory canal caused by organisms susceptible to the action of the antimicrobial, complicated by swelling
ADVERSE REACTIONS SIGNIFICANT — Frequency not defined: Otic: Transient burning or stinging may be noticed occasionally when the solution is first instilled into the acutely inflamed ear
CONTRAINDICATIONS — Hypersensitivity to acetic acid, propylene glycol, hydrocortisone, or any component of the formulation; perforated tympanic membrane; herpes simplex; vaccinia, and varicella
DRUG INTERACTIONS — Hydrocortisone: Substrate of CYP3A4 (minor); Induces CYP3A4 (weak)
PRICING — (data from drugstore.com)Solution (Acetasol HC) 2-1% (10): $16.07
PHARMACOLOGIC CATEGORY Otic Agent, Anti-infective
DOSING: ADULTS — Otitis externa (superficial): Otic: Instill 3-5 drops in ear(s) every 4-6 hours
DOSING: PEDIATRIC — Children 3 years: Refer to adult dosing.
DOSING: ELDERLY — Refer to adult dosing.
DOSAGE FORMS — Excipient information presented when available (limited, particularly for generics); consult specific product labeling.
Solution, otic drops: Acetic acid 2%, propylene glycol diacetate 3%, and hydrocortisone 1% (10 mL)
DOSAGE FORMS: CONCISE Solution, otic drops: Acetic acid 2%, propylene glycol diacetate 3%, and hydrocortisone 1% (10 mL) Acetasol® HC, VoSol® HC: Acetic acid 2%, propylene glycol diacetate 3%, and hydrocortisone 1% (10 mL)
GENERIC EQUIVALENT AVAILABLE — Yes
ADMINISTRATION — After removing cerumen and debris, solution may be applied by inserting a cotton wick into the ear canal and saturating with the solution. Wick may remain in place for 24 hours and then removed; however, drops should continue to be instilled into ear canal as long as indicated.
USE — Treatment of superficial infections of the external auditory canal caused by organisms susceptible to the action of the antimicrobial, complicated by swelling
ADVERSE REACTIONS SIGNIFICANT — Frequency not defined: Otic: Transient burning or stinging may be noticed occasionally when the solution is first instilled into the acutely inflamed ear
CONTRAINDICATIONS — Hypersensitivity to acetic acid, propylene glycol, hydrocortisone, or any component of the formulation; perforated tympanic membrane; herpes simplex; vaccinia, and varicella
DRUG INTERACTIONS — Hydrocortisone: Substrate of CYP3A4 (minor); Induces CYP3A4 (weak)
PRICING — (data from drugstore.com)Solution (Acetasol HC) 2-1% (10): $16.07
Acetic acid:
U.S. BRAND NAMES — VoSol® [DSC]
PHARMACOLOGIC CATEGORY Otic Agent, Anti-infectiveTopical Skin Product
DOSING: ADULTS Irrigation (Note: Dosage of an irrigating solution depends on the capacity or surface area of the structure being irrigated): For continuous irrigation of the urinary bladder with 0.25% acetic acid irrigation, the rate of administration will approximate the rate of urine flow; usually 500-1500 mL/24 hours For periodic irrigation of an indwelling urinary catheter to maintain patency, about 50 mL of 0.25% acetic acid irrigation is required
Otitis externa: Otic: Insert saturated wick; keep moist 24 hours; remove wick and instill 5 drops 3-4 times/day
DOSING: ELDERLY — Refer to adult dosing.
DOSAGE FORMS — Excipient information presented when available (limited, particularly for generics); consult specific product labeling. [DSC] = Discontinued product
Solution for irrigation: 0.25% (250 mL, 500 mL, 1000 mL)
Solution, otic (VoSol® [DSC]): 2% (15 mL)
DOSAGE FORMS: CONCISE Solution for irrigation: 0.25% (250 mL, 500 mL, 1000 mL)
Solution, otic: 2% (15 mL)
GENERIC EQUIVALENT AVAILABLE — Yes
ADMINISTRATION — Not for internal intake or I.V. infusion; topical use or irrigation use only.
USE — Irrigation of the bladder; treatment of superficial bacterial infections of the external auditory canal
ADVERSE REACTIONS SIGNIFICANT — <1% (Limited to important or life-threatening): Hematuria, systemic acidosis, urologic pain
CONTRAINDICATIONS — Hypersensitivity to acetic acid or any component of the formulation; during transurethral procedures
WARNINGS / PRECAUTIONS — Not for internal intake or I.V. infusion; topical use or irrigation use only. Use of irrigation in patients with mucosal lesions of urinary bladder may cause irritation. Systemic acidosis may result from absorption.
PREGNANCY RISK FACTOR — C (show table)
PHARMACOLOGIC CATEGORY Otic Agent, Anti-infectiveTopical Skin Product
DOSING: ADULTS Irrigation (Note: Dosage of an irrigating solution depends on the capacity or surface area of the structure being irrigated): For continuous irrigation of the urinary bladder with 0.25% acetic acid irrigation, the rate of administration will approximate the rate of urine flow; usually 500-1500 mL/24 hours For periodic irrigation of an indwelling urinary catheter to maintain patency, about 50 mL of 0.25% acetic acid irrigation is required
Otitis externa: Otic: Insert saturated wick; keep moist 24 hours; remove wick and instill 5 drops 3-4 times/day
DOSING: ELDERLY — Refer to adult dosing.
DOSAGE FORMS — Excipient information presented when available (limited, particularly for generics); consult specific product labeling. [DSC] = Discontinued product
Solution for irrigation: 0.25% (250 mL, 500 mL, 1000 mL)
Solution, otic (VoSol® [DSC]): 2% (15 mL)
DOSAGE FORMS: CONCISE Solution for irrigation: 0.25% (250 mL, 500 mL, 1000 mL)
Solution, otic: 2% (15 mL)
GENERIC EQUIVALENT AVAILABLE — Yes
ADMINISTRATION — Not for internal intake or I.V. infusion; topical use or irrigation use only.
USE — Irrigation of the bladder; treatment of superficial bacterial infections of the external auditory canal
ADVERSE REACTIONS SIGNIFICANT — <1% (Limited to important or life-threatening): Hematuria, systemic acidosis, urologic pain
CONTRAINDICATIONS — Hypersensitivity to acetic acid or any component of the formulation; during transurethral procedures
WARNINGS / PRECAUTIONS — Not for internal intake or I.V. infusion; topical use or irrigation use only. Use of irrigation in patients with mucosal lesions of urinary bladder may cause irritation. Systemic acidosis may result from absorption.
PREGNANCY RISK FACTOR — C (show table)
Acetic acid, propylene glycol diacetate, and hydrocortisone
U.S. BRAND NAMES — Acetasol® HC; VoSol® HC
PHARMACOLOGIC CATEGORY Otic Agent, Anti-infective
DOSING: ADULTS — Otitis externa (superficial): Otic: Instill 3-5 drops in ear(s) every 4-6 hours
DOSING: PEDIATRIC — Children 3 years: Refer to adult dosing.
DOSING: ELDERLY — Refer to adult dosing.
DOSAGE FORMS — Excipient information presented when available (limited, particularly for generics); consult specific product labeling.
Solution, otic drops: Acetic acid 2%, propylene glycol diacetate 3%, and hydrocortisone 1% (10 mL)
DOSAGE FORMS: CONCISE Solution, otic drops: Acetic acid 2%, propylene glycol diacetate 3%, and hydrocortisone 1% (10 mL) Acetasol® HC, VoSol® HC: Acetic acid 2%, propylene glycol diacetate 3%, and hydrocortisone 1% (10 mL)
GENERIC EQUIVALENT AVAILABLE — Yes
ADMINISTRATION — After removing cerumen and debris, solution may be applied by inserting a cotton wick into the ear canal and saturating with the solution. Wick may remain in place for 24 hours and then removed; however, drops should continue to be instilled into ear canal as long as indicated.
USE — Treatment of superficial infections of the external auditory canal caused by organisms susceptible to the action of the antimicrobial, complicated by swelling
ADVERSE REACTIONS SIGNIFICANT — Frequency not defined: Otic: Transient burning or stinging may be noticed occasionally when the solution is first instilled into the acutely inflamed ear
CONTRAINDICATIONS — Hypersensitivity to acetic acid, propylene glycol, hydrocortisone, or any component of the formulation; perforated tympanic membrane; herpes simplex; vaccinia, and varicella
DRUG INTERACTIONS — Hydrocortisone: Substrate of CYP3A4 (minor); Induces CYP3A4 (weak)
PRICING — (data from drugstore.com)Solution (Acetasol HC) 2-1% (10): $16.07
PATIENT INFORMATION — See individual agents for Acetic Acid and Hydrocortisone.
(For additional information see "Acetic acid, propylene glycol diacetate, and hydrocortisone: Patient drug information")
PHARMACOLOGIC CATEGORY Otic Agent, Anti-infective
DOSING: ADULTS — Otitis externa (superficial): Otic: Instill 3-5 drops in ear(s) every 4-6 hours
DOSING: PEDIATRIC — Children 3 years: Refer to adult dosing.
DOSING: ELDERLY — Refer to adult dosing.
DOSAGE FORMS — Excipient information presented when available (limited, particularly for generics); consult specific product labeling.
Solution, otic drops: Acetic acid 2%, propylene glycol diacetate 3%, and hydrocortisone 1% (10 mL)
DOSAGE FORMS: CONCISE Solution, otic drops: Acetic acid 2%, propylene glycol diacetate 3%, and hydrocortisone 1% (10 mL) Acetasol® HC, VoSol® HC: Acetic acid 2%, propylene glycol diacetate 3%, and hydrocortisone 1% (10 mL)
GENERIC EQUIVALENT AVAILABLE — Yes
ADMINISTRATION — After removing cerumen and debris, solution may be applied by inserting a cotton wick into the ear canal and saturating with the solution. Wick may remain in place for 24 hours and then removed; however, drops should continue to be instilled into ear canal as long as indicated.
USE — Treatment of superficial infections of the external auditory canal caused by organisms susceptible to the action of the antimicrobial, complicated by swelling
ADVERSE REACTIONS SIGNIFICANT — Frequency not defined: Otic: Transient burning or stinging may be noticed occasionally when the solution is first instilled into the acutely inflamed ear
CONTRAINDICATIONS — Hypersensitivity to acetic acid, propylene glycol, hydrocortisone, or any component of the formulation; perforated tympanic membrane; herpes simplex; vaccinia, and varicella
DRUG INTERACTIONS — Hydrocortisone: Substrate of CYP3A4 (minor); Induces CYP3A4 (weak)
PRICING — (data from drugstore.com)Solution (Acetasol HC) 2-1% (10): $16.07
PATIENT INFORMATION — See individual agents for Acetic Acid and Hydrocortisone.
(For additional information see "Acetic acid, propylene glycol diacetate, and hydrocortisone: Patient drug information")
Acetic acid, propylene glycol diacetate, and hydrocortisone
U.S. BRAND NAMES — Acetasol® HC; VoSol® HC
PHARMACOLOGIC CATEGORY Otic Agent, Anti-infective
DOSING: ADULTS — Otitis externa (superficial): Otic: Instill 3-5 drops in ear(s) every 4-6 hours
DOSING: PEDIATRIC — Children 3 years: Refer to adult dosing.
DOSING: ELDERLY — Refer to adult dosing.
DOSAGE FORMS — Excipient information presented when available (limited, particularly for generics); consult specific product labeling.
Solution, otic drops: Acetic acid 2%, propylene glycol diacetate 3%, and hydrocortisone 1% (10 mL)
DOSAGE FORMS: CONCISE Solution, otic drops: Acetic acid 2%, propylene glycol diacetate 3%, and hydrocortisone 1% (10 mL) Acetasol® HC, VoSol® HC: Acetic acid 2%, propylene glycol diacetate 3%, and hydrocortisone 1% (10 mL)
GENERIC EQUIVALENT AVAILABLE — Yes
ADMINISTRATION — After removing cerumen and debris, solution may be applied by inserting a cotton wick into the ear canal and saturating with the solution. Wick may remain in place for 24 hours and then removed; however, drops should continue to be instilled into ear canal as long as indicated.
USE — Treatment of superficial infections of the external auditory canal caused by organisms susceptible to the action of the antimicrobial, complicated by swelling
ADVERSE REACTIONS SIGNIFICANT — Frequency not defined: Otic: Transient burning or stinging may be noticed occasionally when the solution is first instilled into the acutely inflamed ear
CONTRAINDICATIONS — Hypersensitivity to acetic acid, propylene glycol, hydrocortisone, or any component of the formulation; perforated tympanic membrane; herpes simplex; vaccinia, and varicella
DRUG INTERACTIONS — Hydrocortisone: Substrate of CYP3A4 (minor); Induces CYP3A4 (weak)
PRICING — (data from drugstore.com)Solution (Acetasol HC) 2-1% (10): $16.07
PATIENT INFORMATION — See individual agents for Acetic Acid and Hydrocortisone.
(For additional information see "Acetic acid, propylene glycol diacetate, and hydrocortisone: Patient drug information")
PHARMACOLOGIC CATEGORY Otic Agent, Anti-infective
DOSING: ADULTS — Otitis externa (superficial): Otic: Instill 3-5 drops in ear(s) every 4-6 hours
DOSING: PEDIATRIC — Children 3 years: Refer to adult dosing.
DOSING: ELDERLY — Refer to adult dosing.
DOSAGE FORMS — Excipient information presented when available (limited, particularly for generics); consult specific product labeling.
Solution, otic drops: Acetic acid 2%, propylene glycol diacetate 3%, and hydrocortisone 1% (10 mL)
DOSAGE FORMS: CONCISE Solution, otic drops: Acetic acid 2%, propylene glycol diacetate 3%, and hydrocortisone 1% (10 mL) Acetasol® HC, VoSol® HC: Acetic acid 2%, propylene glycol diacetate 3%, and hydrocortisone 1% (10 mL)
GENERIC EQUIVALENT AVAILABLE — Yes
ADMINISTRATION — After removing cerumen and debris, solution may be applied by inserting a cotton wick into the ear canal and saturating with the solution. Wick may remain in place for 24 hours and then removed; however, drops should continue to be instilled into ear canal as long as indicated.
USE — Treatment of superficial infections of the external auditory canal caused by organisms susceptible to the action of the antimicrobial, complicated by swelling
ADVERSE REACTIONS SIGNIFICANT — Frequency not defined: Otic: Transient burning or stinging may be noticed occasionally when the solution is first instilled into the acutely inflamed ear
CONTRAINDICATIONS — Hypersensitivity to acetic acid, propylene glycol, hydrocortisone, or any component of the formulation; perforated tympanic membrane; herpes simplex; vaccinia, and varicella
DRUG INTERACTIONS — Hydrocortisone: Substrate of CYP3A4 (minor); Induces CYP3A4 (weak)
PRICING — (data from drugstore.com)Solution (Acetasol HC) 2-1% (10): $16.07
PATIENT INFORMATION — See individual agents for Acetic Acid and Hydrocortisone.
(For additional information see "Acetic acid, propylene glycol diacetate, and hydrocortisone: Patient drug information")
Acetic acid
U.S. BRAND NAMES — VoSol® [DSC]
PHARMACOLOGIC CATEGORY Otic Agent, Anti-infectiveTopical Skin Product
DOSING: ADULTS Irrigation (Note: Dosage of an irrigating solution depends on the capacity or surface area of the structure being irrigated): For continuous irrigation of the urinary bladder with 0.25% acetic acid irrigation, the rate of administration will approximate the rate of urine flow; usually 500-1500 mL/24 hours For periodic irrigation of an indwelling urinary catheter to maintain patency, about 50 mL of 0.25% acetic acid irrigation is required
Otitis externa: Otic: Insert saturated wick; keep moist 24 hours; remove wick and instill 5 drops 3-4 times/day
DOSING: ELDERLY — Refer to adult dosing.
DOSAGE FORMS — Excipient information presented when available (limited, particularly for generics); consult specific product labeling. [DSC] = Discontinued product
Solution for irrigation: 0.25% (250 mL, 500 mL, 1000 mL)
Solution, otic (VoSol® [DSC]): 2% (15 mL)
DOSAGE FORMS: CONCISE Solution for irrigation: 0.25% (250 mL, 500 mL, 1000 mL)
Solution, otic: 2% (15 mL)
GENERIC EQUIVALENT AVAILABLE — Yes
ADMINISTRATION — Not for internal intake or I.V. infusion; topical use or irrigation use only.
USE — Irrigation of the bladder; treatment of superficial bacterial infections of the external auditory canal
ADVERSE REACTIONS SIGNIFICANT — <1% (Limited to important or life-threatening): Hematuria, systemic acidosis, urologic pain
CONTRAINDICATIONS — Hypersensitivity to acetic acid or any component of the formulation; during transurethral procedures
WARNINGS / PRECAUTIONS — Not for internal intake or I.V. infusion; topical use or irrigation use only. Use of irrigation in patients with mucosal lesions of urinary bladder may cause irritation. Systemic acidosis may result from absorption.
PREGNANCY RISK FACTOR — C (show table)
PHARMACOLOGIC CATEGORY Otic Agent, Anti-infectiveTopical Skin Product
DOSING: ADULTS Irrigation (Note: Dosage of an irrigating solution depends on the capacity or surface area of the structure being irrigated): For continuous irrigation of the urinary bladder with 0.25% acetic acid irrigation, the rate of administration will approximate the rate of urine flow; usually 500-1500 mL/24 hours For periodic irrigation of an indwelling urinary catheter to maintain patency, about 50 mL of 0.25% acetic acid irrigation is required
Otitis externa: Otic: Insert saturated wick; keep moist 24 hours; remove wick and instill 5 drops 3-4 times/day
DOSING: ELDERLY — Refer to adult dosing.
DOSAGE FORMS — Excipient information presented when available (limited, particularly for generics); consult specific product labeling. [DSC] = Discontinued product
Solution for irrigation: 0.25% (250 mL, 500 mL, 1000 mL)
Solution, otic (VoSol® [DSC]): 2% (15 mL)
DOSAGE FORMS: CONCISE Solution for irrigation: 0.25% (250 mL, 500 mL, 1000 mL)
Solution, otic: 2% (15 mL)
GENERIC EQUIVALENT AVAILABLE — Yes
ADMINISTRATION — Not for internal intake or I.V. infusion; topical use or irrigation use only.
USE — Irrigation of the bladder; treatment of superficial bacterial infections of the external auditory canal
ADVERSE REACTIONS SIGNIFICANT — <1% (Limited to important or life-threatening): Hematuria, systemic acidosis, urologic pain
CONTRAINDICATIONS — Hypersensitivity to acetic acid or any component of the formulation; during transurethral procedures
WARNINGS / PRECAUTIONS — Not for internal intake or I.V. infusion; topical use or irrigation use only. Use of irrigation in patients with mucosal lesions of urinary bladder may cause irritation. Systemic acidosis may result from absorption.
PREGNANCY RISK FACTOR — C (show table)
Acetic acid
U.S. BRAND NAMES — VoSol® [DSC]
PHARMACOLOGIC CATEGORY Otic Agent, Anti-infectiveTopical Skin Product
DOSING: ADULTS Irrigation (Note: Dosage of an irrigating solution depends on the capacity or surface area of the structure being irrigated): For continuous irrigation of the urinary bladder with 0.25% acetic acid irrigation, the rate of administration will approximate the rate of urine flow; usually 500-1500 mL/24 hours For periodic irrigation of an indwelling urinary catheter to maintain patency, about 50 mL of 0.25% acetic acid irrigation is required
Otitis externa: Otic: Insert saturated wick; keep moist 24 hours; remove wick and instill 5 drops 3-4 times/day
DOSING: ELDERLY — Refer to adult dosing.
DOSAGE FORMS — Excipient information presented when available (limited, particularly for generics); consult specific product labeling. [DSC] = Discontinued product
Solution for irrigation: 0.25% (250 mL, 500 mL, 1000 mL)
Solution, otic (VoSol® [DSC]): 2% (15 mL)
DOSAGE FORMS: CONCISE Solution for irrigation: 0.25% (250 mL, 500 mL, 1000 mL)
Solution, otic: 2% (15 mL)
GENERIC EQUIVALENT AVAILABLE — Yes
ADMINISTRATION — Not for internal intake or I.V. infusion; topical use or irrigation use only.
USE — Irrigation of the bladder; treatment of superficial bacterial infections of the external auditory canal
ADVERSE REACTIONS SIGNIFICANT — <1% (Limited to important or life-threatening): Hematuria, systemic acidosis, urologic pain
CONTRAINDICATIONS — Hypersensitivity to acetic acid or any component of the formulation; during transurethral procedures
WARNINGS / PRECAUTIONS — Not for internal intake or I.V. infusion; topical use or irrigation use only. Use of irrigation in patients with mucosal lesions of urinary bladder may cause irritation. Systemic acidosis may result from absorption.
PREGNANCY RISK FACTOR — C (show table)
PHARMACOLOGIC CATEGORY Otic Agent, Anti-infectiveTopical Skin Product
DOSING: ADULTS Irrigation (Note: Dosage of an irrigating solution depends on the capacity or surface area of the structure being irrigated): For continuous irrigation of the urinary bladder with 0.25% acetic acid irrigation, the rate of administration will approximate the rate of urine flow; usually 500-1500 mL/24 hours For periodic irrigation of an indwelling urinary catheter to maintain patency, about 50 mL of 0.25% acetic acid irrigation is required
Otitis externa: Otic: Insert saturated wick; keep moist 24 hours; remove wick and instill 5 drops 3-4 times/day
DOSING: ELDERLY — Refer to adult dosing.
DOSAGE FORMS — Excipient information presented when available (limited, particularly for generics); consult specific product labeling. [DSC] = Discontinued product
Solution for irrigation: 0.25% (250 mL, 500 mL, 1000 mL)
Solution, otic (VoSol® [DSC]): 2% (15 mL)
DOSAGE FORMS: CONCISE Solution for irrigation: 0.25% (250 mL, 500 mL, 1000 mL)
Solution, otic: 2% (15 mL)
GENERIC EQUIVALENT AVAILABLE — Yes
ADMINISTRATION — Not for internal intake or I.V. infusion; topical use or irrigation use only.
USE — Irrigation of the bladder; treatment of superficial bacterial infections of the external auditory canal
ADVERSE REACTIONS SIGNIFICANT — <1% (Limited to important or life-threatening): Hematuria, systemic acidosis, urologic pain
CONTRAINDICATIONS — Hypersensitivity to acetic acid or any component of the formulation; during transurethral procedures
WARNINGS / PRECAUTIONS — Not for internal intake or I.V. infusion; topical use or irrigation use only. Use of irrigation in patients with mucosal lesions of urinary bladder may cause irritation. Systemic acidosis may result from absorption.
PREGNANCY RISK FACTOR — C (show table)
Subscribe to:
Posts (Atom)